Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Biopharma firm UCB brings new arthritis therapy to China

    By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2019-12-16 16:59
    Share
    Share - WeChat

    Belgium-based global biopharmaceutical company UCB announced the commercial launch of an innovative biological therapy to treat moderate-to-severe active rheumatoid arthritis (RA) for adult patients in China, marking the expansion of company's business footprint to immune system diseases in the country.

    The injection that patients are suggested to take every two weeks is the first biological agent approved in China to be used for female RA patients both during pregnancy and lactation if clinically needed.

    Doctors said RA is an autoimmune disease that causes chronic joint inflammation and affects 5 million people in China. The number of women patients suffering from the disease is three times that of the opposite gender, and women at childbearing age usually have to face the dilemma between postponing starting a family and suspending disease treatment with traditional therapies.

    Tian Xinping, chief physician of the department of rheumatology and immunology of the Peking Union Medical College Hospital, said if the disease is not well controlled for women before and during pregnancy, it may increase the risk of adverse pregnancy outcomes, such as preterm birth, low birth weight and preeclampsia. RA also comes with high disease relapse rate after giving birth, she said.

    Taco van Tiel, vice-president and head of international markets of UCB, said the product with novel molecular structure made world debut in Switzerland 12 years ago and so far has been available in 56 countries and benefiting over 380,000 patients.

    "We're delighted to bring this novel medicine to Chinese patients living with challenging chronic inflammatory conditions. UCB has a long heritage in immunology and now China has built an active pipeline of innovative portfolios reflecting UCB's global strengths," he said.

    Wu Xin, managing director of UCB China, said about five innovative molecules, including those treating autoimmune disease and osteoporosis, are scheduled by the company to be launched in the China market over the next five years.

    "For two drugs, China is part of the global Phase III clinical trial simultaneously," he said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    宅男在线国产精品无码| 亚洲Av无码精品色午夜| 国产做无码视频在线观看浪潮| 亚洲中文字幕久久精品无码喷水| 日韩丰满少妇无码内射| 中文字幕一区二区三区在线不卡| 天堂在线资源中文在线8 | 久久无码AV中文出轨人妻| 精品久久久久久无码人妻蜜桃 | 在线看片福利无码网址| 中文字幕无码精品亚洲资源网久久| 国精品无码一区二区三区左线| 亚洲欧洲自拍拍偷午夜色无码| 久久久久综合中文字幕| 亚洲欧美日韩在线中文字幕 | 无码精品日韩中文字幕| 久久久久久无码国产精品中文字幕| 亚洲AV日韩AV高潮无码专区| 日韩精品无码人成视频手机| 最近中文字幕在线| 一区二区中文字幕| 日韩美无码五月天| 惠民福利中文字幕人妻无码乱精品| 精品无码久久久久国产| 无码免费一区二区三区免费播放 | 中文字幕丰满乱子伦无码专区| 中文字幕免费视频| 成人精品一区二区三区中文字幕| 亚洲一区二区三区在线观看精品中文| 久久久无码精品午夜| 国产免费久久久久久无码| AA区一区二区三无码精片| 精品国产一区二区三区无码| 国产日韩精品中文字无码| av无码免费一区二区三区| 99无码熟妇丰满人妻啪啪| 久久精品无码专区免费| 亚洲无码黄色网址| 亚洲一区二区三区无码中文字幕| 精品久久久久久中文字幕| 国产资源网中文最新版|